Foundation Medicine, Inc.
One Kendall Square
183 articles with Foundation Medicine, Inc.
Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda’s Late-Stage Lung Cancer Portfolio
Companion diagnostics will be developed to identify patients with NSCLC that harbor ALK fusions and EGFR Exon20 insertion mutations to match patients with appropriate targeted therapies from Takeda
FDA Approves Foundation Medicine's FoundationOne®Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer
FDA Approves Foundation Medicine's FoundationOne ® Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer FDA Approval Includes Companion Diagnostic Claims for Rubraca ® (rucaparib), the First PARP Inhibitor Approved in a Prostate Cancer Setting, and Three Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer FoundationOne Liquid CDx Analyzes More Than 300 Genes a
With a new regulatory approval in hand for its comprehensive pan-tumor liquid biopsy test, Foundation Medicine said it plans for the product to be available for commercial use by Friday, Aug. 28.
OneOncology and Foundation Medicine Unveil First-of-its-Kind Partnership to Advance Personalized Medicine at Community Oncology Practices
Groundbreaking Collaboration Advances Precision Oncology Informed by Comprehensive Genomic Profiling in Community Cancer Care, Where the Majority of Patients in the U.S. Are Treated CAMBRIDGE, Mass. & NASHVILLE, Tenn.--( BUSINESS WIRE )-- Foundation Medicine, Inc. and OneOncology today announced a new joint initiative that is intended to better enable OneOncology partner practice physicians to unlock the potential of precision oncology throug
FoundationOne®CDx Receives FDA Approval as the First Companion Diagnostic to Identify Advanced Cancer Patients with Solid Tumors that are Tumor Mutational Burden-High and Appropriate for Immunotherapy Treatment with KEYTRUDA® (pembrolizumab)
Foundation Medicine, Inc., announced that the US FDA approved FoundationOne®CDx as a companion diagnostic for KEYTRUDA®, Merck’s anti-PD-1 therapy, which was also approved under accelerated approval for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high [≥10 mutations/megabase ] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Foundation Medicine Appoints Dr. Geoffrey Oxnard as Vice President, Global Medical Lead, Liquid Franchise
Foundation Medicine, Inc., today announced the appointment of Dr. Geoffrey R. Oxnard as vice president, global medical lead for the Company’s liquid biopsy portfolio, effective immediately.
Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May Cause Treatment Resistance in Patients with METex14-altered NSCLC
Alterations that cause skipping of exon 14 on the MET gene (METex14) are drivers of a type of lung cancer with a poor prognosis, but that is treatable with a recently approved MET inhibitor
Foundation Medicine Receives FDA Approval for FoundationOne®CDx as the Companion Diagnostic for LYNPARZA® to Identify Patients with HRR-Mutated Metastatic Castration-Resistant Prostate Cancer
LYNPARZA was approved based on positive results from the PROfound study for which Foundation Medicine served as the Next-Generation Sequencing (NGS) partner
Foundation Medicine Receives FDA Approval for FoundationOne®CDx as the Companion Diagnostic for Tabrecta™ (capmatinib), the Only FDA-Approved MET Inhibitor for Patients With Metastatic Non-Small Cell Lung Cancer With METex14
Foundation Medicine, Inc. announced that FoundationOne®CDx has been approved by the U.S. Food and Drug Administration for use as the companion diagnostic to aid in identifying patients with non-small cell lung cancer for whom treatment with Tabrecta™ may be appropriate.
Foundation Medicine Receives FDA Approval for FoundationOne®CDx as the Companion Diagnostic for Pemazyre™ (pemigatinib), the First FDA-Approved Targeted Therapy for Adults with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
Foundation Medicine, Inc. announced that the US FDA approved FoundationOne®CDx as the registrational companion diagnostic for Incyte’s Pemazyre™, a selective fibroblast growth factor receptor inhibitor approved for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test.
Foundation Medicine and Chugai Announce Partnership with National Cancer Center for the Use of FoundationOne®Liquid in the Third Stage of SCRUM-Japan
SCRUM-Japan aims to apply blood-based genomic insights to inform and accelerate the development of precision medicine approaches for patients with advanced cancers
Oncology industry veteran to lead product sales and operations efforts
Foundation Medicine Expands Indication for FoundationOne®CDx as a Companion Diagnostic for Piqray® (alpelisib)
Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for Piqray®
Foundation Medicine, Inc. and Natera, Inc. announced a partnership to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays, for use by biopharmaceutical and clinical customers who order FoundationOne®CDx.
Renowned oncology leader to head scientific innovation at Foundation Medicine
Foundation Medicine Expands Indication for FoundationOne®CDx as a Companion Diagnostic for LYNPARZA® (Olaparib)
Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for LYNPARZA® (Olaparib) for first line maintenance therapy in BRCA-mutated advanced ovarian cancer. FoundationOne CDx is an FDA-approved comprehensive genomic profiling (CGP) test for all solid tumors that incorporates multiple companion diagnostics.
This is the largest fund in the 12 years Third Rock has been in existence. The company indicates it will use the money to seed 10 to 12 life science companies.
Bayer and Foundation Medicine announce global collaboration to develop next-generation sequencing (NGS)-based companion diagnostics in oncology
Bayer AG and Foundation Medicine, Inc. announced a global collaboration for the development and commercialization of NGS-based companion diagnostics.
The first project the companies aim to develop is a companion diagnostic for Vitrakvi, the only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors.
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.